High-dose hepatitis B immunoglobulin therapy in hepatocellular carcinoma with hepatitis B virus-DNA/hepatitis B e antigen-positive patients after living donor liver transplantation

doi:10.3748/wjg.v22.i14.3803

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 14

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7508)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-2) series.

Item

Count

PDF

473

WORD

254

HTML

4052

Figures (1-4)

166

Tables (1-2)

150

Sum=5095

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

871

Download

1542

Sum=2413

Apr 14, 2016 (publication date) through May 7, 2024

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Apr 14, 2016; 22(14): 3803-3812
Published online Apr 14, 2016. doi: 10.3748/wjg.v22.i14.3803

Open in New Tab Full Size Figure Download Figure

Figure 1 Hepatocellular carcinoma recurrence-free survival rate of the low-dose hepatitis B immunoglobulin group and high-dose hepatitis B immunoglobulin group before adjustment with propensity scores among hepatocellular carcinoma patients who met the Milan criteria (A) and did not meet the Milan criteria (B); hepatitis B recurrence-free survival rate of the low-dose hepatitis B immunoglobulin group group and high-dose hepatitis B immunoglobulin group group before adjustment with propensity scores among hepatocellular carcinoma patients who met the Milan criteria (C) and did not meet the Milan criteria (D). HBIG: Hepatitis B Immunoglobulin; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma.

Open in New Tab Full Size Figure Download Figure

Figure 2 Overall survival rate of the low-dose hepatitis B immunoglobulin group and high-dose hepatitis B Immunoglobulin group before adjustment with propensity scores among hepatocellular carcinoma patients who met the Milan criteria (A) and did not meet the Milan criteria (B). HBIG: Hepatitis B Immunoglobulin.

Open in New Tab Full Size Figure Download Figure

Figure 3 Hepatocellular carcinoma recurrence-free survival rate of the low-dose hepatitis B immunoglobulin group and high-dose hepatitis B immunoglobulin group after adjustment with propensity scores among hepatocellular carcinoma patients who met the Milan criteria (A) and did not meet the Milan criteria (B); hepatitis B recurrence-free survival rate of the low-dose hepatitis B immunoglobulin group group and high-dose hepatitis B immunoglobulin group group after adjustment with propensity scores among hepatocellular carcinoma patients who met the Milan criteria (C) and did not meet the Milan criteria (D). HBIG: Hepatitis B Immunoglobulin; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma.

Open in New Tab Full Size Figure Download Figure

Figure 4 Overall survival rate of the low-dose hepatocellular carcinoma group and high-dose hepatocellular carcinoma group after adjustment with propensity scores among hepatocellular carcinoma patients who met the Milan criteria (A) and did not meet the Milan criteria (B). HBIG: Hepatitis B Immunoglobulin.

Citation: Lee EC, Kim SH, Lee SD, Park H, Lee SA, Park SJ. High-dose hepatitis B immunoglobulin therapy in hepatocellular carcinoma with hepatitis B virus-DNA/hepatitis B e antigen-positive patients after living donor liver transplantation. World J Gastroenterol 2016; 22(14): 3803-3812
URL: https://www.wjgnet.com/1007-9327/full/v22/i14/3803.htm
DOI: https://dx.doi.org/10.3748/wjg.v22.i14.3803